The expression of activating receptors NKG2D and DNAM-1 on NK cells also modulate their lysis capability in patients with acute myelogenous leukemia (AML), myelodysplastic syndrome, multiple myeloma, and ovarian carcinoma [18,31,32,33]. Here, KLRK1 is linked to acute myeloid leukemia.